Navigation Links
Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology

Potential Earlier Identification of Toxicity, Efficacy for Pharmaceutical


REDWOOD CITY, Calif., Aug. 29 /PRNewswire/ -- Codexis, Inc., a private biotechnology company and leading developer of clean manufacturing processes, today announced it has licensed important intellectual property from the California Institute of Technology for preparing and identifying drug metabolites (substances produced during drug metabolism). Codexis will incorporate this technology in development of new R&D productivity tools for use by the pharmaceutical industry.

This technology is based on development of a family of diverse variants of bacterial cytochrome P450 enzymes by Frances Arnold, Ph.D., Dick and Barbara Dickinson Professor of Chemical Engineering and Biochemistry, Cal Tech. Dr. Arnold will join the Codexis Industrial Advisory Board.

"This enzyme family can facilitate identification of safer, more efficacious drugs earlier in the drug development process by expediting the production of potential human metabolites of drug candidates," said Peter Seufer-Wasserthal, Ph.D., Vice President and General Manager, Codexis Pharma Services Group. "Additionally, this technology can be used for lead diversification and complements the human cytochrome biocatalyst products and services at BioCatalytics, acquired by Codexis in July."

"Current metabolite identification and synthesis methods are based on classical chemistry methods, which can be slow and cumbersome," he added. "Combining Codexis' leading position as a developer of biocatalytic products and processes for the pharmaceutical industry with the techniques developed by Dr. Arnold will enable us to provide a powerful, efficient new tool set for rapid identification and synthesis of drug metabolites. These new tools could add considerable value in metabolite profiling as well as lead diversification in drug discovery."

Drug metabolites are produced by the body during the break-down (metabolism) of drugs. Primary metabolites are largely formed in the liver by human P450 enzymes to aid in elimination of a drug from the body. In some cases, metabolites can be toxic, while for other drugs, "active" metabolites have shown improved efficacy and lower toxicity than the administered drug substance. The US Food and Drug Administration now recommends metabolic characterization for all new investigational human therapeutics.

Codexis, Inc. is a leading developer of clean biocatalytic process technologies that can substantially reduce the cost of manufacturing across a broad range of industries. Codexis' proprietary directed evolution technologies enable novel solutions for efficient, cost-effective and environmentally friendly processes for pharmaceutical, energy and industrial chemical applications. In 2006, the company was recognized by the U.S. EPA with a Presidential Green Chemistry Challenge Award. Codexis is a registered trademark of Codexis, Inc. For more information please visit

Contact: Justin Jackson, of Burns McClellan, 212-213-0006, or Lyn Christenson, Codexis,, 650-298-5368.

SOURCE Codexis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. GenTel licenses next generation cancer research
2. Third Wave licenses Innogenetics tech to settle lawsuit
3. WARF licenses patents for new glaucoma drug treatment
4. PKWARE Licenses Technology to Expand SecureZIP Standard
5. Mentor Licenses Botulinum From WARF and Plans Wisconsin Manufacturing Facility
6. Simultaneous Determination of Residues of Approximately 100 Pesticides and Metabolites in Fruit and Vegetables by LC/MS/MS
7. Detection of nitrofurane metabolites in food with HPLC/MS/MS
8. Simultaneously characterizing and quantifying chloramphenicol and its metabolite using LC/MS/MS
9. High sensitivity quantitation of metabolites of nitrofuran antibiotics in animal tissue using LC/MS/MS
10. Analysis of Nitrofurans Metabolites by Positive Ion Electrospray LC/MS/MS
11. Simultaneous Detection of CYP3A4, CYP2D6 and CYP2C9 Metabolites with a Single, Sensitive, LC/MS/MS Method
Post Your Comments:
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... SILVER SPRING, Md. , June 23, 2016 ... evidence collected from the crime scene to track the criminal ... sick, and the U.S. Food and Drug Administration (FDA) uses ... Sound far-fetched? It,s not. ... whole genome sequencing to support investigations of foodborne illnesses. Put ...
(Date:6/23/2016)... ... 2016 , ... Charm Sciences, Inc. is pleased to announce ... Research Institute approval 061601. , “This is another AOAC-RI approval of the Peel ... President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably to ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
Breaking Biology Technology:
(Date:4/19/2016)... 2016 The new GEZE SecuLogic ... web-based "all-in-one" system solution for all door components. It ... the door interface with integration authorization management system, and ... The minimal dimensions of the access control and the ... installations offer considerable freedom of design with regard to ...
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting Medicaid ... setting a new clinical standard in telehealth thanks to ... leveraging the higi platform, IMPOWER patients can routinely track ... and body mass index, and, when they opt in, ... convenient visit to a local retail location at no ...
(Date:3/23/2016)... , March 23, 2016 ... erhöhter Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender ... das Unternehmen mit SpeechPro zusammenarbeitet, um erstmals ... Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im Rahmen ...
Breaking Biology News(10 mins):